Early cancer detection is known to improve clinical outcome. For screening purposes, it is possible to make a diagnosis of malignancy by cytological analysis, circumventing the need for an invasive procedure and tissue biopsy. Minimally invasive methods of harvesting cellular specimens from an anatomical site include direct sampling of surface cells by taking a smear or brushings. This simple approach forms the basis of population screening for cervical cancer, in which cervical smears are processed for cytological assessment with the Papanicolau (Pap) stain to determine both nuclear morphology and the extent of keratinocyte differentiation. 1 At present, this represents an effective screening method for the detection of pre-malignant or early invasive lesions of the uterine cervix, for which prompt treatment intervention reduces disease mortality.
present throughout the cell cycle, MCMs and related DNA replication proteins are degraded in quiescent and differentiated human cells. 3 We predicted that, in the evolution of the cancer cell, replication proteins including MCMs would be a critical requirement from a very early stage in the process of malignant transformation, and in turn serve as accurate biomarkers for cancer diagnosis.
MCM proteins (MCMs 2-7) are abundant in all cycling human cells, forming ring-shaped heterohexameric complexes that may function as replicative helicases during the synthesis (S) phase. 4 Upon cell-cycle exit, MCMs are no longer required, so they are downregulated and absent in quiescent, differentiated or senescent cell states. Most cells in the human body are not cycling and exist in a state of quiescence or terminal differentiation (in G 0 phase), so MCM immunolabelling is restricted to a minority of cycling cells (in phases G 1 , S or G 2 or mitosis of the cell cycle) located at specific tissue sites, such as epithelia and bone marrow. Consequently, it is possible to precisely identify populations of cycling cells in human tissue sections using antibodies specifically raised against MCM proteins. This is exemplified by immunohistochemical staining of normal stratified epithelium of the ectocervix with MCM antibodies (see Figure 1) . 2 Cells in cycle are confined to the basal proliferative layers of normal cervical epithelium and stain positively for MCMs, whereas superficial keratinocytes are MCM-negative, having exited the cell cycle and undergone terminal differentiation (see Figure 1a) . In contrast, there is a striking difference in MCM immunolabelling in pre-malignant lesions, where the proliferating cellular compartment is expanded and extends to the 
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Dysregulated expression of MCMs is also characteristic of dysplasia and malignancy in a range of other anatomical sites, including breast, 6 lung, 7, 8 colorectal, 9 oesophageal, 10 prostate, 11 ovarian, 12 laryngeal, 13 oral, 14 Diagnosis exfoliated cells present in bodily fluids. 17 In colorectal cancer, for example, cytological preparations can be made from stool specimens, and the MCM immunodiagnostic test also facilitates detection of pre-malignant or malignant cells using this method. Although the yield of colonocyte retrieval from stool samples can be low, an initial evaluation study has shown that MCM-positive colonocytes could be retrieved from the stool samples of 37 out of 40 patients with established colorectal cancer prior to their definitive management by surgery. 18 Most interestingly, all of 25 control participants in this study shed only MCM-negative colonocytes in the stool.
MCM immunostaining identifies cycling cells in the basal proliferative layers of normal cervical epithelium (a), as well as in the expanded proliferative compartments of low-grade (b) and highgrade (c) squamous intraepithelial lesions. Using a routine Pap stain, abnormal surface cervical epithelial cells (present in the centre of the field) are difficult to visualise in a routine conventional cervical smear (d) but are clearly distinct in an MCM immunoenhanced sample (e). Originally published in
Identification of neoplastic cells using antibodies against MCMs can also be applied in population screening for early detection of cancer at a range of other body sites from exfoliated cells obtained for screening purposes, such as urine samples for bladder cancer and sputum samples for lung cancer. Technically, it is also possible to automate detection of MCMs in situ using high-throughput microscopy of such samples or in lysed specimens using a liquid-phase immunoassay.
Conclusions
In recent years, relatively few advances have been made in improving existing cancer screening methods, in contrast to the continuous development of new anticancer agents entering clinical practice. For many cancer types, the reason why screening programmes cannot be developed quickly is that the important precursor lesions have not yet been clearly defined. Therefore, there is an urgent need to improve our understanding of the pathogenesis of cancer for each primary site.
New insights into the biological mechanisms that are critical in the formation of the cancer cell will lead to the development of diagnostic biomarkers that can also be exploited as screening tools. In this respect, MCMs have been shown to be sensitive cell-cycle biomarkers for early cancer detection. It is not surprising that expression microarray analyses have independently identified the strength of these proteins for this specific application. 19 Other proteins that regulate the initiation of DNA replication are also of translational importance and may complement MCM staining in predicting clinical behaviour. 6 For example, geminin is a regulator of MCMs in human cells that identifies actively proliferating cancer cells in S, G 2 and early mitotic phases of the cell cycle, 20, 21 and a high geminin labelling index is associated with poor survival and the development of distant metastases in patients with invasive breast cancer. 22, 23 Replication proteins may also prove to be of value as strong biomarkers that predict response to treatments such as radiotherapy. 24 Targeting factors required for the initiation of DNA replication is another exciting area of research that may yield highly effective anticancer therapeutic agents in the future. ■
